Research Insights 3 min readUpdated
Semax Research Guide: Animal Mechanisms and Human Imaging Evidence
Compare selected Semax studies by model and endpoint, separating rat BDNF and gene-expression work from a small human imaging study.
Key answer
Selected Semax papers investigate rat neurotrophin signalling, gene expression after experimental ischaemia and brain-network imaging in a small group of people. These are different evidence types and do not collectively establish a general cognitive benefit for every user or preparation.
Compare research formats
View current prices, availability and analytical-document status on each product page. These catalogue formats are for laboratory research; they are not equivalent to medicines or materials used in a cited study.
Semax research brings together experiments that answer different questions. A useful overview keeps the model, measurement and uncertainty next to each finding.
Selected evidence by study type
| Source | Model and measurement | Limit to preserve |
|---|---|---|
| Dolotov et al., 2006 | Rat hippocampal BDNF/trkB measurements and a behavioural task | Animal findings are not a general human cognitive outcome |
| Medvedeva et al., 2017 | Gene-expression analysis in rats with experimental cerebral ischaemia | Model-specific transcript changes do not establish clinical recovery |
| Human imaging study, 2018 | Resting-state fMRI in 24 healthy volunteers | An imaging change is not the same endpoint as sustained cognitive improvement |
Read mechanism findings within the experiment
The 2006 rat study reported changes in hippocampal BDNF-related measures. The 2017 work examined gene expression after experimental ischaemia and implicated immune-response processes. These papers can inform mechanistic questions, but their findings should retain the species, intervention and laboratory setting.
What the human imaging paper can support
The 2018 study compared 14 participants receiving Semax with 10 receiving placebo and measured resting-state brain-network patterns shortly after administration. It reported a difference in a default-mode-network component. Its small sample and imaging endpoint matter when interpreting the result; the experiment was not a demonstration of a broad long-term cognitive benefit.
Questions for a stronger evidence summary
- Was the material and formulation clearly identified?
- Were the findings independently replicated in a comparable model?
- Did the experiment measure the outcome claimed in the summary?
- Are adverse findings and uncertainty retained?
- Does a human study actually address the population and time period of interest?
Connect evidence with identity
A label on a research vial does not establish equivalence to a study preparation. Use the analytical report guide for batch-document interpretation. The neuropeptide research topic links related compounds while preserving their separate identities.
This is a guide to selected primary studies, not a systematic review or a complete current trial registry. The editorial standards explain the evidence labels and correction process.
Sources and further reading
- Semax regulates BDNF and trkB expression in the rat hippocampusDolotov et al. - Brain Research, 2006
- Semax regulates expression of immune response genes during ischemic brain injury in ratsMedvedeva et al. - Molecular Genetics and Genomics, 2017
- Effects of Semax on the Default Mode Network of the BrainHuman resting-state fMRI study - Bulletin of Experimental Biology and Medicine, 2018
Update record
: Rebuilt the summary with verified primary-study identities, explicit animal/human model labels and a source table. Clarified the small human imaging study and removed promotional outcome language.
